(Date:11/6/2009)...EO, Calif., Nov. 6 ,...transfer of Qutenza(TM) E.U. Marketing Authorizati...nt progress in commercial readiness activities Ex... Director, Marketing; and Director, Commercial Ope... director and Audit Committee chairman , Up...
(Date:11/6/2009)..., Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biote...e "Company") today announced updated results from ...ients with sarcomas metastatic to the lung in a po...ssue Oncology Society Meeting held in Miami Beach,...sentation, entitled "A Phase II Study of Intraveno...
(Date:11/6/2009)... The agenda for Arrowhead’s 2010...ich is set to take place on February 22-24, 2010 i...day conference we will highlight key issues in for...share their experiences. , ...agenda for Arrowhead’s 2010 Personalized Me...
(Date:11/5/2009)...SBURG, Md., Nov. 5 GenVe...cial results for the third quarter ended September...ion ($0.04 per share) for the three months ended S...illion ($0.08 per share) in the comparable quarter...2009, GenVec,s net loss was $14.1 million ($0.15 p...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6...ee will play host to the 2007 BIO Mid-America Vent...ry Organization and the Wisconsin Biotechnology & ...ed to draw around 90 venture capitalists and somew...apolis, at least six Wisconsin biotech companies a...waukee location may draw more. , ,"We held many co...
"Dasher" virus can turn off security applications
...aire, Wis. Small Tree Communications , which ma...eceive $3.4 million in federal appropriations to m...U.S. Army. , ,The money is part of the fiscal year...its U.S. representative Dave Obey, D-Wausau, with ... to begin working on the development of a faster a...
Other Biology Technology:(Date:11/6/2009)... celebrate the 150th anniversary this month of the...ican Institute of Biological Sciences (AIBS) is pu...out Charles Darwin and his historic insights into ... of the University of California, Berkeley, and Ja...n,s article, "Ten Myths About Charles Darwin," app...
(Date:11/5/2009)...w Haven, Conn.Researchers at Yale University have ... the body,s immune response to HIV and HIV-infecte...r findings, published online in the Journal of th...therapeutic approaches for these diseases. , Th...targeting HIV" (ARM-H) and "antibody-recruiting mo...
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Dr Chugay 28drchugay com 29 Revolutionary Weight Loss Surgery 52165 1Dr Chugay 28drchugay com 29 Revolutionary Weight Loss Surgery 52165 2NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 1NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 2NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 3NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 4NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 5NACDS Urges Clarifications Enhancements in Two Pharmacy Reimbursement Provisions in House Healthcare Reform Legislation 52163 6Genetic Variation Associated With Survival Advantage in African Americans With HIV 52161 1Genetic Variation Associated With Survival Advantage in African Americans With HIV 52161 2Genetic Variation Associated With Survival Advantage in African Americans With HIV 52161 3Genetic Variation Associated With Survival Advantage in African Americans With HIV 52161 4Anti-AANAT Antibody, Unconjugated from CHEMICON
Anti-Rac1 / 2 / 3 Monoclonal Antibody, Unconjugated, Clone L129 from Cell Signaling Technology
Sheep Anti-EBNA 3B Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Mouse C5a Receptor (CD88) Monoclonal Antibody, Unconjugated, Clone 10 / 92 from Cell Sciences
Biology Products: